Together with erlotinib or gefitinib, DCA has been shown to decrease the viability and cell proliferation of, and promote apoptosis in, EGFR-mutant, NCI-H1975, and NCI-H1650, but not in A549 or NCI-H460 NSCLC cell lines, which do not harbor EGFR mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.